Starling Oncology, Inc.(STLN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,879 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
STLN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Starling Oncology, Inc. (STLN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STLN at 45.2/100 on a 32-signal composite quality model, placing it at rank #1,879 of 2,962 stocks — the bottom half of the AI-ranked universe. STLN scores in the top quartile across revenue growth (87.1). Areas of concern include balance sheet strength (10.5) and free cash flow (25.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Starling Oncology, Inc. reports quarterly revenue of $161.3M, net income of $-9.8M, an operating margin of -2.9%. Top institutional holders of STLN by reported 13-F value include BlackRock, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. STLN trades on the Nasdaq exchange and files with the SEC under CIK 1799191. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Starling Oncology, Inc. directly from SEC EDGAR. Starling Oncology, Inc.'s 13F Pro composite quality score has ranged between 32 and 64 since 2024, currently 45.2 — an improving long-term trajectory across 55 quarterly and live scoring snapshots.
Revenue
Q2 2026
$161.3M
Net Income
Q2 2026
$-9.8M
Free Cash Flow
Q2 2026
$11.0M
Operating Margin
Q2 2026
-2.9%
ROIC
Q2 2026
-33.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+27.8% YoYNet Income
+6.3% YoYOperating Income
+40.0% YoYEPS (Diluted)
+23.9% YoYTotal Assets
-4.7% YoYTotal Debt
-16.9% YoYOp. Cash Flow
+7.4% YoYFree Cash Flow
+8.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $502.7M +27.8% | $393.4M +21.3% | $324.2M +28.4% | $252.5M +24.4% | $203.0M +8.3% | $187.5M |
| Net Income | $-60.6M +6.3% | $-64.7M +22.2% | $-83.1M -54750.0% | $152.0K +101.4% | $-10.9M -31.0% | $-8.3M |
| Operating Income | $-36.1M +40.0% | $-60.1M +21.9% | $-77.0M +6.0% | $-82.0M -78.7% | $-45.9M -6605.7% | $-683.9K |
| EPS (Diluted) | $-0.54 +23.9% | $-0.71 +22.8% | $-0.92 -338.1% | $-0.21 -31.2% | $-0.16 -166.7% | $-0.06 |
| Total Assets | $164.7M -4.7% | $172.7M -17.5% | $209.2M -20.0% | $261.7M +28.6% | $203.4M -12.1% | $231.3M |
| Total Debt | $77.4M -16.9% | $93.1M +7.3% | $86.8M +7.7% | $80.6M +21927.6% | $366.0K -97.9% | $17.3M |
| Operating Cash Flow | $-24.6M +7.4% | $-26.5M +26.9% | $-36.3M +41.2% | $-61.8M -89.0% | $-32.7M -5510.0% | $-582.5K |
| Free Cash Flow | $-27.8M +8.4% | $-30.3M +25.8% | $-40.9M +39.2% | $-67.3M -89.4% | $-35.5M -1899.8% | $-1.8M |
Get alerted when STLN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Starling Oncology, Inc. including:
Top Institutional Holders of STLN
BlackRock, Inc.
$25.8M4,749,030 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$18.2M3,360,052 shVANGUARD CAPITAL MANAGEMENT LLC
$17.7M3,265,531 shJOSH ARNOLD INVESTMENT CONSULTANT, LLC
$13.4M2,464,359 shGEODE CAPITAL MANAGEMENT, LLC
$10.3M1,899,998 shGOLDMAN SACHS GROUP INC
$9.4M1,735,337 shWEXFORD CAPITAL LP
$9.3M1,711,323 shSTATE STREET CORP
$8.4M1,552,917 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$8.3M1,520,100 shNuveen, LLC
$7.6M1,408,720 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $25.8M | 4,749,030 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $18.2M | 3,360,052 |
| VANGUARD CAPITAL MANAGEMENT LLC | $17.7M | 3,265,531 |
| JOSH ARNOLD INVESTMENT CONSULTANT, LLC | $13.4M | 2,464,359 |
| GEODE CAPITAL MANAGEMENT, LLC | $10.3M | 1,899,998 |
| GOLDMAN SACHS GROUP INC | $9.4M | 1,735,337 |
| WEXFORD CAPITAL LP | $9.3M | 1,711,323 |
| STATE STREET CORP | $8.4M | 1,552,917 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8.3M | 1,520,100 |
| Nuveen, LLC | $7.6M | 1,408,720 |
Companies Similar to STLN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
electroCore, Inc.
EXAGEN INC.
Neuronetics, Inc.
Apyx Medical Corp
LAKELAND INDUSTRIES INC
Airsculpt Technologies, Inc.
PTC THERAPEUTICS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put STLN on your watchlist
Track score changes the day Starling Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is STLN a good stock to buy?
13F Pro's AI-powered analysis of Starling Oncology, Inc. (STLN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STLN are available on the STLN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. STLN is classified as a small company.
Which hedge funds own STLN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STLN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Starling Oncology, Inc.'s investment landscape.